Roberta Rovito
Milan, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Astrocyte/monocyte activation and inflammation are associated with asymptomatic neurocognitive impairment in people with HIV on suppressive antiretroviral therapy.
Journal: AIDS (London, England)
Published: November 19, 2025
Age and viral replication, not vertical HIV acquisition, drive inflammation and T-cell dysfunction in heavily treatment experienced: data from the Prestigio Registry.
Journal: AIDS (London, England)
Published: July 29, 2025
Early Combination Antiretroviral Therapy Initiation During Primary HIV Infection Restricts HIV Reservoirs and Gut-Driven Inflammation but Fails to Rewire the Systemic Cytokine Landscape.
Journal: Open forum infectious diseases
Published: July 08, 2025
Three-Month cART Initiated During Primary HIV Does Not Correct the Structural, Immune, and Microbial Abnormalities within the Gastrointestinal Tract.
Journal: Pathogens & immunity
Published: July 07, 2025
Investigating the Interplay of SARS-CoV-2 RNAemia and Peripheral Inflammation in Platelet Dysfunction During Acute SARS-CoV-2 Infection.
Journal: Pathogens & immunity
Published: April 16, 2025
Multi-layered deep immune profiling, SARS-CoV-2 RNAemia and inflammation in unvaccinated COVID-19 individuals with persistent symptoms.
Journal: Communications medicine
Published: January 14, 2025
Comparable gut mucosal breakdown and microbial translocation in severe COVID-19 with and without HIV infection.
Journal: AIDS (London, England)
Published: October 23, 2024
Markers of T-cell dysfunction and not inflammaging predict the waning of humoral responses to SARS-CoV-2 mRNA booster vaccination in people with HIV.
Journal: AIDS (London, England)
Published: July 10, 2024
Long-term immune responses to SARS-CoV-2 Omicron BA.4/5 mRNA booster in people living with HIV.
Journal: Communications medicine
Published: May 17, 2024
Short and long-term trajectories of the post COVID-19 condition: Results from the EuCARE POSTCOVID study.
Journal: BMC infectious diseases
Published: May 14, 2024
Clinical Outcome and 7-Day Virological Clearance in High-Risk Patients with Mild-Moderate COVID-19 Treated with Molnupiravir, Nirmatrelvir/Ritonavir, or Remdesivir.
Journal: Infectious diseases and therapy
Published: April 04, 2024
Association between SARS-CoV-2 RNAemia, skewed T cell responses, inflammation, and severity in hospitalized COVID-19 people living with HIV.
Journal: iScience
Published: May 23, 2023
Last Updated: 09/26/2026